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Abstract
Introduction: Thyroid gland is a rare site of clinically detectable tumor metastasis.
Case report: A 71-year-old woman was referred to our department for an evaluation of toxic
multinodular substernal goiter. She had a history of renal clear cell carcinoma of the left kidney,
which had been resected 2 years previously. US confirmed the multinodular goiter. Total
thyroidectomy with neuromonitoring was performed on March 2008. A histological examination
revealed a solitary metastasis of a clear cell renal cancer in a diffuse multinodular goiter. No distant
metastases are detected.
Conclusion: Although uncommon, it is important for the endocrine surgeon and endocrine
oncologist to be able to recognize and differentiate intrathyroid metastases from more primary
common thyroid neoplasms. The diagnosis can be suspected if the patient has a thyroid tumor and
a past history of extrathyroid cancer. These tumors, on the whole, tend to behave more
aggressively and, in most cases, the use of multimodality therapy is recommended.
Introduction
Thyroid cancer refers to any kind of malignant tumors of
the thyroid gland [1,2]. Thyroid cancers can be classified
according to their pathological characteristics and origin
in primary and secondary (i.e. metastases) [1,2].
The four main types of primary thyroid cancer are papil-
lary, follicular, medullary, and anaplastic thyroid cancer
[3]. Papillary and follicular carcinoma are the most com-
mon form of differentiated follicular cell-derived carcino-
mas and comprises 90–95% of all newly diagnosed
thyroid cancers [3]. Medullary thyroid cancer is a rare and
aggressive type of cancer deriving from the parafollicular
cells and accounting for 5% of all thyroid carcinomas [4].
Other rare types of primary thyroid malignant tumors are
squamous cell carcinoma, mucoepidermoid carcinoma,
sclerosing mucoepidermoid with eosinophilia, teratomas,
mucinous carcinoma, spindle cell tumor, lymphomas and
carcinoma showing thymus-like element [5-13]. The thy-
roid gland is a rare site of clinically detectable tumor
metastasis: a palpable thyroid tumor is usually assumed
to be a primary thyroid tumor [14].
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Thyroid Research 2008, 1:6 http://www.thyroidresearchjournal.com/content/1/1/6This report describes herein a patient with solitary metas-
tasis to the thyroid, who had undergone a left nephrec-
tomy for renal clear cell carcinoma 2 years previously.
Unique pathological figures are presented.
Case report
A 71-year-old woman underwent nephrectomy of the
right kidney for renal clear cell carcinoma on September
26, 2006. The tumor measured 28 mm in size and was
localized in the upper pole of the right kidney. The tumor
had been incidentally demonstrated on routine ultra-
sonography (US). Preoperative whole body CT-scan was
negative for local and distant metastases. In the final his-
tological examination, the tumor extended into a renal
vein, regional nodes could not be assessed (pT3b, pNX,
G2). The surgical margin was free of the tumor. Her post-
operative course was uneventful. Neither postoperative
adjuvant chemotherapy nor interferon was given.
In September 2006, she was also referred to the Depart-
ment of Clinical Medicine, Division of Endocrinology, for
an evaluation of toxic substernal goiter with chronic thy-
roiditis. She had no complaints that could be related to
thyroid dysfunction, nor stridor, hoarseness, dysphagia. A
multinodular goiter was noticed at palpation. The patient
underwent antithyroid medication with methimazole.
On January 2008 the patient underwent new endocrine
consultation. Her general health condition was excellent.
She was euthyroid and all laboratory data were normal.
US demonstrated diffuse, bilateral and well-demarcated
micro and micronodules both normooechoic and hypoe-
choic containing high-echo spots representing small calci-
fications measuring 13 × 14 × 18 mm, 14 × 17 × 17 mm,
16 × 16 × 14 mm and 16 × 22 × 20 mm. She underwent a
total thyroidectomy with intraoperative neuromonitoring
(NIM-Response 2.0 System, Medtronic Xomed, Jackson-
ville, Florida).
Five mm-thick sections were stained with hematoxylin-
eosin (H&E) for histopathologic examination. Additional
3 mm-thick sections, collected on positively charges slides
(SuperFrost®Plus, Menzel GmbH & Co KG, Braunsch-
weig) were used for immunohistochemical analysis. The
immunostainings for CD10 (clone 56 CG) and TTF-1
(Thyroid Transcription Factor, clone 8G7G3/1) were per-
formed with an automated immunostainer (Benchmark
XT, Ventana Medical Systems).
At macroscopic examination the thyroid was enlarged,
with a distorted shape, the left lobe being larger than the
right one. On cross section, the gland was occupied by
multiple nodules, some of which were partially cystic and
showed areas of calcification and haemorrhage. A histo-
logical diagnosis of nodular hyperplasia was formulated.
In addition, as shown in figure 1, nodule with a golden
yellow cut surface, measuring 1 cm in its larger dimen-
sion, was observed in the left lobe. Microscopically, the
nodule was surrounded by a complete fibrous capsule and
showed a proliferation of large cells with abundant opti-
cally clear cytoplasm and sharply outlined boundaries,
arranged in nests and cords. The nuclei showed mild to
moderate atypia and single or multiple nucleoli were vis-
ible at ×400 magnification. The neoplastic cells were
strongly immunoreactive for CD10, which is commonly
expressed in renal cell carcinomas. By contrast, TTF-1 was
completely negative, and this ruled out a primary tumour
of the thyroid. Based on these findings and on the similar-
ity of this proliferation with the renal cell neoplasm diag-
nosed in the kidney two years before, a diagnosis of a
intrathyroid metastasis of renal cell carcinoma, grade II,
was made.
Her postoperative course was uneventful.
Postoperative bone scintigraphy and computer tomogra-
phy also revealed the absence of any other metastases. She
has been doing well without any evidence of recurrence
for 5 months after thyroidectomy.
Discussion
The prevalence of intrathyroid metastases of nonthyroid
origin ranges from 1.9% to 25% [15-24]. Mortensen et al.
account 4% of patients with metastatic neoplasm with
secondary tumors to the thyroid gland [25]. Silverberg
meticulously examined the gland and found an incidence
of 25% in patients dying from disseminated malignant
tumor of other primary [26].
Primary carcinomas of the lung, kidney, breast, stomach
are the most common tumors metastasizing to the thyroid
[15-24]. Carcinomas of the colon, gynecologic tumors,
oral cavity, esophagus, neuroendocrine cancers, and sar-
comas have been rarely published only in case reports or
small series [15-24]. In the study of Shimaoka et al.,
metastases to the thyroid gland occurred in 39% of
melanoma patients, 21% of breast cancer patients, 12%
renal cancer, 10% of lung cancer and 10% of patients with
primary head and neck tumors [27]. Chen et al. reported
ten patients with thyroid metastases and 50% of these
patients had metastases from renal cell carcinoma [28].
Thus, renal cell carcinoma is by far the most common
source of clinically relevant metastases to the thyroid
gland [28].
However, considering that the reported metastases of
autopsy cases included nonclinically metastasis (i.e.
occult cancer or widespread cancer at the time of death), a
better estimate of the incidence of clinically apparent
metastases to the thyroid has been shown in clinical stud-Page 2 of 5
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appears to be lower than the incidence found in autopsy.
According to Shimaoka, the thyroid metastases were
rarely clinically apparent in only 5% to 10% of the
patients [27]. Wychulis et al. described that only 10 of
20262 patients, who had undergone thyroidectomy at the
Mayo Clinic, had symptomatic metastatic involvement of
the thyroid gland [29].
In clinical practice, in a patient with a diffuse and bilateral
multinodular goiter, a correct diagnosis is difficult, since
there are no specific findings of metastatic thyroid tumor
on ultrasonography or computer tomography scan inves-
tigations. Elliott and Frantz found 44 reported cases of
metastatic carcinoma that had been misidentified as pri-
mary thyroid cancer [14].
Therefore, a correct diagnosis of metastatic thyroid tumors
requires a careful consideration of patients with a history
of cancer. This information immediately stratifies a
patient into a high risk category.
Moreover, the presentation of a thyroid nodule years after
the treatment of a primary cancer often poses a diagnostic
dilemma. Often there is a latency period lasting years
between the diagnosis of the primary cancer and the
appearance of the thyroid mass [30]. Latent intervals of up
to 20 years have also been reported [30]. This finding is
especially true for renal primary tumors [30]. In these
cases with a long interval between the detection of the pri-
mary tumor and the development of the thyroid metasta-
sis, the difficulty in making a correct diagnosis could
increase as well.
Histopathology of renal cell carcinoma metastasis in the thyroid: capsulated intrathyroidal nodule (A) composed of nests and cords of large clea  cells (B) with abundant optically emp y cytoplasm, sharply ou lined boundari s and moderately atypic l nuclei (C)Figure 1
Histopathology of renal cell carcinoma metastasis in the thyroid: capsulated intrathyroidal nodule (A) com-
posed of nests and cords of large clear cells (B) with abundant optically empty cytoplasm, sharply outlined 
boundaries and moderately atypical nuclei (C). The clear cells are CD10-immunoreactive (D). (H&E, ×10, ×100 and 
×400; avidin-biotin-peroxidase, ×400).Page 3 of 5
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metastasis to the thyroid, which appeared prior to the pri-
mary tumor being detected [31].
Fine needle aspiration cytology (FNA) can allow for the
preoperative diagnosis of a secondary tumor, thus chang-
ing the preoperative work-up of such patient [32-34].
Once the diagnosis of metastatic disease has been con-
firmed on FNA, the patient should undergo a metastatic
work-up to rule out other distant metastases [32-34].
Finally, if technically feasible, thyroidectomy can be effec-
tive for local control [35]. Surgical resection is regarded as
the best treatment for a metastatic thyroid tumor, espe-
cially if the primary carcinoma appears to be controlled
and there is no evidence of metastasis elsewhere [36].
Moreover, considering the size and rapid growth of the
thyroid tumor, even if the patient had already had other
metastatic lesions, thyroidectomy would still be required
in order to relieve tracheal compression. This is especially
true for tumors that present years after the treatment of the
primary cancer.
Survival time after diagnosis of the thyroid metastases is
determined by the biology of the primary disease [32-36].
Our patient has no evidence of recurrence 5 months after
thyroid surgery. Authors have demonstrated that for iso-
lated thyroid metastases, thyroidectomy has prolonged
survival. Chen et al. reported that 60% of the patients with
solitary thyroid metastasis were still alive after a thyroid-
ectomy during a median follow-up period of 5.2 years
[28].
After surgical management, the administration of sys-
temic therapy is recommended [35].
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